Irritable Bowel Syndrome (IBS): A Nutrition and Natural-Health Reference
1. Definition and Clinical Presentation
Irritable bowel syndrome (IBS) is a common, chronic disorder of gut-brain interaction characterized by recurrent abdominal pain and altered bowel habits, including constipation, diarrhea, or both. It is further described as a complex functional gastrointestinal disorder characterized by chronic or recurrent abdominal pain, stool irregularities, and bloating. Despite its high prevalence and significant impact on quality of life, IBS often remains underdiagnosed or mismanaged, leading to excessive diagnostic testing, unnecessary specialty referrals, and increased healthcare costs.
1.1 Diagnostic Criteria: Rome IV
Under Rome IV, irritable bowel syndrome is defined as recurrent abdominal pain occurring on average at least 1 day per week in the last 3 months, with symptom onset at least 6 months before diagnosis, and associated with two or more of: related to defecation, associated with a change in stool frequency, or associated with a change in stool form (appearance).
Two critical changes from Rome III stand out. First, "discomfort" was removed — only "pain" qualifies. This was controversial because many patients describe their primary symptom as discomfort or pressure rather than pain, potentially excluding them from diagnosis. Second, the frequency threshold increased from 3 days per month to 1 day per week, a more stringent bar that reduced global IBS prevalence estimates from approximately 11 percent to about 4 percent.
1.2 Subtypes
IBS subtypes are now classified exclusively by predominant stool form using the Bristol Stool Form Scale on days with abnormal bowel habits. The four recognized subtypes are:
- IBS-C (constipation-predominant): features Bristol types 1–2 in more than 25 percent of abnormal bowel movements and types 6–7 in less than 25 percent.
- IBS-D (diarrhea-predominant): is the reverse.
- IBS-M (mixed bowel habits): has both types exceeding 25 percent.
- IBS-U (unsubtyped): fits none of these patterns.
Rome IV clarifies that functional bowel disorders exist on a spectrum of symptoms. The IBS subtype can be re-categorized as a person's bowel habits change.
1.3 Prevalence and Epidemiology
IBS has a prevalence of 10 to 25% in the United States and has a high disease burden, as evidenced by reduced quality of life, decreased work productivity, and increased healthcare utilization and costs. The pooled prevalence of IBS in 53 studies that used the Rome III criteria, from 38 countries and comprising 395,385 participants, was 9.2% (95% CI 7.6–10.8; I² = 99.7%). The prevalence of IBS was higher in women than in men (12.0% vs 8.6%; odds ratio 1.46 [95% CI 1.33–1.59]). Prevalence varied substantially between individual countries, and this variability persisted even when the same diagnostic criteria were applied and identical methodology was used in studies.
In terms of subtype distribution in a large US cross-sectional study using Rome IV criteria, IBS-M was found in 33.9% of cases, IBS-C in 33.6%, IBS-D in 28.1%, and IBS-U in 4.4%.
2. Body Systems Involved
IBS is not confined to the gastrointestinal tract alone; multiple interacting physiological systems are implicated in its expression and perpetuation.
2.1 The Gut-Brain Axis
Disruptions to the gut–brain axis, the bidirectional communication system between the central nervous system and the enteric nervous system, are hypothesised to be at the core of irritable bowel syndrome. The brain-gut microbiome axis is formed with the complex communication through neuronal, endocrine, and immune signaling between microbiota and the Central Nervous System (CNS). The gut microbiota is influenced by the CNS with the stress-mediator-induced virulence gene expression and the control of gastrointestinal functions, including motility and immune modulation through the Autonomic Nervous System (ANS). Additionally, the Enteric Nervous System (ENS) is also involved in the alteration of gastrointestinal functions causing changes in the composition of the microbiota.
2.2 The Enteric Nervous System and Serotonin Signaling
Patients with IBS have demonstrated increased vulnerability to neurotransmitter imbalances, with abnormalities associated with changes in gastrointestinal motility, low-grade inflammation, and visceral pain. The intestinal microbiota exerts a profound influence on the mechanisms underlying IBS, and one notable effect of this interaction is the regulation of serotonin, also known as 5-hydroxytryptamine (5-HT), which is released from enterochromaffin cells. Serotonin is a key neurotransmitter regulating peristalsis, secretion, and visceral sensitivity within the gut wall.
2.3 The Immune System and Low-Grade Inflammation
Recent studies have linked IBS pathogenesis with low-grade mucosal inflammation. A combination of low-grade mucosal inflammation with visceral hypersensitivity and impaired bowel motility could be the underlying etiology for IBS pathogenesis. This condition may arise from compromised epithelial barrier, post-infectious alterations, dysbiosis, and altered stress levels, which stimulate aberrant immune responses.
Although the aetiology of IBS has not yet been completely elucidated, various factors have a role, including composition of the gut microbiota, intestinal permeability, immune cell reactivity and sensitivity of the enteric nervous system, the brain–gut axis (spinal, vagal or pelvic pathways) or the brain. Results from a 2025 systematic review and meta-analysis showed significantly elevated pro-inflammatory markers in individuals with IBS, including Interleukin (IL)-6.
2.4 The Gut Microbiome
The gut microbiome modulates these processes by influencing neurotransmitter metabolism, immune responses, and epithelial integrity, positioning it as both a driver of symptoms and a promising therapeutic target. Research has concluded that the gut microbiome plays a substantial role in the pathophysiology of IBS. Disruptions in the hypothalamic–pituitary–adrenal axis, impaired serotonin signaling, bile acid malabsorption, and altered intestinal permeability collectively result in the emergence of abnormal motility, visceral hypersensitivity, and chronic inflammation.
2.5 Intestinal Epithelial Barrier
Various pathways might be affected in specific subgroups of patients with IBS: epithelial barrier (permeability), immune function, impaired bile acid metabolism and function, neuronal processing and signal transduction via spinal afferents from the periphery to the central nervous system in addition to the bidirectional crosstalk via the brain–gut axis, presumably contributing to psychological conditions such as anxiety, depression and somatization.
2.6 The Hypothalamic–Pituitary–Adrenal (HPA) Axis
Psychological stress further modulates these pathways via the hypothalamic–pituitary–adrenal (HPA) axis, increasing visceral sensitivity and immune reactivity. Chronic stress and anxiety may significantly exacerbate symptoms through the upregulation of cortisol secretion, disrupting the gut microbiome and elevating visceral sensitivity.
2.7 Visceral Hypersensitivity
Patients with visceral hypersensitivity tend to have lower colonic distension pain threshold, where a normal stimulus will intensify the pain in the patients. This heightened perception of pain within the gastrointestinal tract is one of the most consistently observed features across all IBS subtypes.
2.8 Comorbid Systems: Psychiatric and Extraintestinal
Patients are usually seen suffering from comorbidities such as anxiety, depression, fibromyalgia, migraine, headache, interstitial cystitis, and temporomandibular joint syndrome. IBS was significantly associated with anxiety, behavior, and mood disorders (ORs 1.8–2.4). Among physical conditions, IBS was associated with increased odds of headache, chronic pain, diabetes mellitus, and both insomnia and hypersomnolence-related symptoms (ORs 1.9–4.0). This systems biological model is consistent with the frequent comorbidity of IBS with other so-called functional GI disorders, and with other chronic pain and psychiatric disorders, in particular anxiety.
3. Contributing and Associated Factors
3.1 Post-Infectious Origins
Post-infectious IBS (PI-IBS) occupies 6–17% of the total IBS, and some previous prospective studies reported that 7–33% of acute bacterial enteritis patients developed IBS after 6–12 months of infection. After an enteritis event, an increased number of immunocytes, mast cells, and large amounts of lymphocyte infiltration were revealed in the mucosa and enteric nervous system of the gut. Beside the inflammatory cells, enterochromaffin cells, cytokines, and inducible nitric oxide may be related to the pathophysiologic mechanism of PI-IBS. Associated mucosal inflammation in IBS patients is often linked with a history of infectious gastroenteritis induced by bacteria, parasites, or viruses, which is referred to as post-infectious IBS.
3.2 Dysbiosis and the Gut Microbiome
The specific subgroup of post-infectious IBS is of special interest since it opens the possibility of dysbiosis as the pivotal point for development of IBS in association with traveler's diarrhea or antibiotic treatment with ensuing dysbiosis and abdominal symptoms that may resolve over decades. Altered gastrointestinal motility, visceral hypersensitivity, post-infectious reactivity, brain–gut interactions, alteration in the fecal microbiome, bacterial overgrowth, food sensitivity, carbohydrate malabsorption, and intestinal inflammation have all been studied as mechanisms involved in the pathogenesis of IBS.
3.3 Small Intestinal Bacterial Overgrowth (SIBO)
One of the reasons for a paradigm shift in understanding IBS is the realization that gut dysbiosis, including small intestinal bacterial overgrowth (SIBO), causes IBS symptoms. Between 4% and 78% of patients with IBS and 1% and 40% of controls have SIBO; such wide variations in prevalence might result from population differences, IBS diagnostic criteria, and methods used to diagnose SIBO. A 2020 analysis confirmed that the pooled SIBO rate is significantly higher in IBS subjects than in controls (30 vs 9%, n = 2,494, p < 0.0001). Methanobrevibacter smithii, the causal organism in a positive methane breath test, has been linked to constipation-predominant IBS (IBS-C).
3.4 Food Intolerances and Dietary Triggers
Diet plays a crucial role in IBS pathogenesis through modulating the normal gut microenvironment including decrease in colonic fermentation, altered gut microbiome composition, and reduced antigen activation by the gut immune system. Food and breakdown products of food can affect many aspects of gut physiology including motility, permeability, microbiome, visceral sensation, brain-gut interactions, immune regulation, and neuro-endocrine function; which are all relevant to the pathogenesis of IBS.
3.5 Psychosocial and Stress Factors
Longitudinal studies in humans have shown that people who report symptoms of anxiety and/or depression with no comorbid IBS do develop gastrointestinal symptoms over time, whereas those with a diagnosis of IBS but no anxiety or depressive symptoms at baseline report anxiety or depressive symptoms at follow-up. In a systematic review of 11 studies, people with depression had a twofold higher risk of comorbid IBS and a nearly twofold higher risk of developing new-onset IBS than people without depression.
After full adjustment, chronic stress in the past year was associated with gastrointestinal symptoms (OR: 1.347; 95% CI 1.030–1.762), whereas stress in the past 5 years (OR: 1.415; 95% CI 1.058–1.892) and sleeping onset difficulties ≥ 3 times weekly (OR: 2.153; 95% CI 1.228–3.774) were associated with IBS.
3.6 Genetic and Early-Life Factors
The pathophysiology behind IBS is believed to be multifactorial based on genetic, dietary, gastrointestinal, and central nervous system influences. Multiple factors such as genetic, psychosocial, environmental, visceral hypersensitivity, low-grade inflammation, gastrointestinal motility changes, food components, and intestinal microbiota are thought to play a role in the disease process of IBS. Early-life adversity, prenatal exposures, and postnatal antibiotic use have also been implicated in the development of IBS, as summarized in the microbiome and IBS literature.
4. Nutrients, Herbs, and Natural Ingredients
Studies indicate that more than one-third of patients with IBS use nonpharmacologic therapies, which include natural products and mind-body therapies, with higher prevalence identified among women, younger individuals, and those with higher education levels. Although some therapies show promise in symptom management, the evidence remains mixed for many of these interventions.
4.1 Dietary Fiber and Psyllium
Traditional Use
Psyllium (Plantago ispaghula) has been used for centuries in Ayurvedic and Persian medical traditions as a demulcent, laxative, and regulator of bowel function. The husks of psyllium seeds were applied as a bulk-forming agent for both constipation and diarrhea, reflecting an appreciation for their ability to modulate stool consistency rather than act in only one direction.
Scientific Evidence
Psyllium husk (Plantago ispaghula) is a soluble fiber commonly recommended for IBS. Psyllium increases water content in the small bowel and ascending and descending colon via its polymers. One of the major drawbacks of fiber is its propensity to increase gas and bloating in a population already experiencing these symptoms, but psyllium may minimize this effect.
A systematic review of fiber and FODMAP-restricted diets found that fiber was beneficial in 5/7 studies in chronic constipation and in 3/3 studies in IBS-C. There were significant disparities in subject selection, interventions, and outcome assessments. Fiber supplementation is considered beneficial in mild to moderate IBS-C, although larger, more rigorous, and long-term RCTs are needed.
An umbrella review of nutritional interventions noted that soluble fiber improved IBS symptoms, while vitamin D3 and curcumin improved IBS symptom severity, and these outcomes have mainly shown small effects and low to very low evidence certainty.
Evidence strength: Moderate for soluble fiber (particularly psyllium) in IBS-C; the overall evidence base is limited by heterogeneity and short study durations.
4.2 Peppermint Oil (Mentha piperita)
Traditional Use
Peppermint has a long history of use in European and Middle Eastern herbal medicine as a carminative and antispasmodic. In traditional European practice, infusions of peppermint leaf were consumed to relieve flatulence, bloating, and abdominal cramping. The volatile oil was recognized as the active component and later formulated as an enteric-coated capsule for targeted release in the intestine. The German Commission E has approved peppermint oil for spastic conditions of the upper GI tract as well as colon irritation.
Scientific Evidence
Peppermint oil (PO) contains L-menthol, which blocks calcium channels in smooth muscle, thus producing antispasmodic effects on the gastrointestinal tract. PO also possesses antimicrobial, anti-inflammatory, antioxidant, immunomodulating, and anesthetic activities, all of which may be relevant for the treatment of IBS.
A 2019 meta-analysis of 12 randomized trials with 835 patients found that for global symptom improvement, the risk ratio (RR) from seven RCTs for the effect of PO (n = 253) versus placebo (n = 254) on global symptoms was 2.39 [95% CI: 1.93, 2.97], I² = 0%, p < 0.00001. A 2022 updated meta-analysis of 10 RCTs concluded that peppermint oil was superior to placebo for the treatment of IBS in terms of both effect on global symptoms and abdominal pain.
A 2022 systematic review across plant-derived treatments concluded that evidence from recent systematic reviews and meta-analyses consistently indicates that peppermint oil is the most effective botanical agent, particularly for reducing abdominal pain and overall IBS symptom severity.
Evidence strength: The strongest botanical evidence base in IBS. Multiple meta-analyses of RCTs consistently show benefit. Limitations include variable trial quality and predominantly short-term follow-up. Enteric-coated formulations are used in research to prevent heartburn from early release in the esophagus.
4.3 Turmeric and Curcumin (Curcuma longa)
Traditional Use
Turmeric (Curcuma longa) has been used in Ayurvedic medicine for at least 4,000 years, primarily as a digestive tonic, carminative, and agent for abdominal pain and inflammatory bowel conditions. In Traditional Chinese Medicine (TCM), the rhizome of related Curcuma species has been applied to relieve pain and move stagnant qi in the digestive system. The spice is also central to South Asian culinary and medicinal culture, used to settle indigestion and as a general anti-inflammatory.
Scientific Evidence
Curcumin, a biologically active phytochemical, has demonstrated anti-inflammatory and anti-oxidant properties and mucosal protective effects in rat models of colitis. In human studies, the findings of the included literature showed that curcumin and turmeric alone or in combination with other medications could improve the severity of IBS as well as the quality of life among people who suffer from IBS symptoms. Overall, medications containing curcumin and turmeric extract, due to these compounds' anti-inflammatory effects, may improve IBS symptoms, particularly abdominal pain and quality of life.
A 2018 meta-analysis that reviewed five RCTs and included three in a formal meta-analysis found that a 2004 UK study that included 207 IBS patients who took turmeric daily for 8 weeks found improvement in abdominal pain/discomfort. A more recent meta-analysis evaluating use of curcumin for IBS included 326 patients from 3 studies and found that curcumin resulted in improved IBS symptoms, although this was not statistically significant (-0.466; 95% CI, -1.113 to 0.182; P = 0.158), and there was heterogeneity across the studies, including lack of consistent IBS definition and different curcumin formulations.
A 2024 systematic review noted that four out of seven studies showed a beneficial effect of curcumin/turmeric supplementation on irritable bowel syndrome. However, a high degree of clinical and methodological heterogeneity across the studies precluded meta-analysis. Descriptive summaries of the evidence demonstrated a mix of statistically significant and non-significant responses to treatment that generally favoured curcumin interventions over placebo.
Evidence strength: Preliminary and mixed. Human clinical evidence is limited by small sample sizes, use of combination products, differing formulations, and lack of consistent IBS diagnostic criteria across trials. Further well-designed RCTs are needed.
4.4 STW 5 / Iberogast (Multi-Herb Preparation)
Traditional Use
Many of the nine herbs in STW 5 have individual traditions in European herbal medicine. Chamomile (Matricaria recutita), lemon balm (Melissa officinalis), peppermint (Mentha piperita), caraway (Carum carvi), and licorice (Glycyrrhiza glabra) all have documented traditional use in German, British, and Mediterranean herbal practice for carminative, antispasmodic, and digestive-soothing purposes. Greater celandine (Chelidonium majus) and bitter candytuft (Iberis amara) also feature in historical European phytotherapeutic texts for biliary and intestinal spasm.
Scientific Evidence
Iberogast, also termed STW 5, is a proprietary combination, in a liquid formulation, of hydroethanolic extracts of nine plants: bitter candytuft (Iberis amara), caraway (Carum carvi), chamomile (Matricaria recutita), peppermint (Mentha piperita), lemon balm (Melissa officinalis), liquorice (Glycyrrhiza glabra), angelica (Angelica archangelica), greater celandine (Chelidonium majus), and milk thistle (Silybum marianum). STW 5 and STW 5-II were compared with placebo for their efficacy and safety in IBS patients in a double-blind, multicentre RCT. Both significantly decreased the IBS symptom score and the total abdominal pain score in an intention-to-treat analysis after 4 weeks of treatment.
Iberogast (STW-5 and STW-5 II) has demonstrated clinical improvements across multiple trials, while curcumin shows mechanistic and preliminary clinical potential by modulating several IBS-related pathways. STW5 (Iberogast®) is a medicinal product that has been shown to promote changes in gastric tone, gastrointestinal motility, intestinal inflammation, and visceral sensitivity.
Evidence strength: Moderate, based on multiple controlled trials and regulatory approval in Germany. Limitations include proprietary formulation making it difficult to attribute effects to individual components, and relatively small trial populations.
4.5 Probiotics
Traditional Use
Fermented foods including yogurt, kefir, and lacto-fermented vegetables have been part of traditional diets across many cultures for millennia — in Central Asia (kefir), Eastern Europe (sauerkraut, kvass), South Asia (lassi), and East Asia (kimchi, miso). These preparations were recognized in folk and traditional medicine as supporting digestive health, though the concept of "probiotics" as defined by microbiology is a modern construct.
Scientific Evidence
Current evidence from systematic reviews and meta-analyses supports the use of probiotics for symptomatic relief of IBS; however, no recommendation on the specific species/strains or combination can be made. Although numerous studies have shown that probiotics are effective in the treatment of IBS, whether particular combinations, species, or strains of probiotics are more effective than others remains unclear. A network meta-analysis showed that different probiotics had different responder rates, and a combination of Lactobacillus and Bifidobacterium might have a better treatment effect on IBS.
An umbrella review published in 2024 found that with regard to abdominal pain after probiotic supplementation (relative risk [RR]: 4.04; 95% CI: 2.36, 6.92; GRADE = moderate) and IBS symptoms after a low-FODMAP diet (RR: 1.48; 95% CI: 1.14, 1.93; GRADE = moderate), there was evidence that probiotics and a low-FODMAP diet can confer clinical and favorable effects.
Systematic review analysis reveals that low-FODMAP diets consistently alleviate IBS symptoms and improve quality of life. However, the effectiveness of probiotics and prebiotics varies, with outcomes dependent on specific strains and individual patient microbiota profiles.
Evidence strength: Moderate overall, though strain- and dose-specific effects cannot yet be reliably generalized. Trials are typically short-term and use heterogeneous preparations. The ACG 2020 guidelines listed probiotics and the low-FODMAP diet as approaches to alleviate IBS symptoms before escalating to medical therapies.
4.6 Aloe Vera (Aloe barbadensis)
Traditional Use
Aloe vera gel and latex have featured prominently in the traditional medicine of North Africa, the Arabian Peninsula, the Caribbean, and indigenous North American peoples. The gel (inner leaf) has been used topically and internally as a demulcent, anti-inflammatory, and laxative agent. In particular, it was applied to soothe mucosal irritation and relieve constipation.
Scientific Evidence
Aloe vera is commonly used in IBS, especially the constipation-predominant subtype. However, clinical trial evidence is limited and inconsistent. A randomized, double-blind, cross-over placebo-controlled study evaluated aloe vera in IBS. Statistical analysis of 47 patients showed no difference between the placebo and aloe vera treatment in quality of life in IBS. In a previous study by Odes et al., 35 men and women were randomized to receive capsules containing celandine-aloe vera-psyllium, or placebo, for 28 days. They reported that abdominal pain was not reduced in either group, but the preparation of herbal medicine was effective as a laxative in the treatment of constipation.
An umbrella review noted that aloe vera improved IBS symptoms in some analyses, while a 2026 systematic review of plant-derived treatments concluded that Aloe vera exhibits mixed or inconsistent results, reflecting heterogeneity in study designs and underlying mechanisms.
Evidence strength: Weak to mixed. Small trial populations, varying preparations, and inconsistent outcomes limit conclusions. More rigorous RCTs are needed.
4.7 Berberine
Traditional Use
Berberine is a benzylisoquinoline alkaloid found in several plants, most notably Coptis chinensis (Chinese goldthread), Berberis vulgaris (barberry), and Hydrastis canadensis (goldenseal). In Traditional Chinese Medicine, Coptis chinensis has been used for thousands of years for conditions described as "damp heat in the gut," manifesting as diarrhea, dysentery, and abdominal pain.
Scientific Evidence
Berberine, a benzylisoquinoline alkaloid isolated from several plants, in particular from Coptis chinensis, has shown therapeutic efficacy in patients affected by IBS-D in an RCT with placebo. On the basis of findings in a murine model of IBS-D, it has been proposed that berberine induces its beneficial effects through stimulation of μ and δ opioid receptors.
Evidence strength: Preliminary. Evidence is largely from a small number of RCTs and animal models. Larger, well-designed trials in diverse IBS populations are needed.
4.8 L-Glutamine
Traditional Use
L-Glutamine is not an ingredient with a classical herbal tradition. Its use in the context of IBS and gut permeability is a contemporary nutritional and functional medicine approach, emerging from research into intestinal barrier function and "leaky gut" in the late 20th and early 21st centuries.
Scientific Evidence
Some patients with IBS-D show increased small bowel and colonic intestinal permeability related to reduced expression of tight junctions. L-glutamine, an essential amino acid, has been postulated to alter tight junction proteins, impact inflammatory signaling, and reduce intestinal permeability. A 2019 study randomized 115 patients with post-infectious IBS-D to receive L-glutamine 5 g three times daily or placebo for 8 weeks.
Evidence strength: Preliminary. This remains an emerging area, with limited clinical trials. Evidence for the mechanism is largely preclinical or derived from small RCTs, particularly in the post-infectious IBS subtype.
4.9 St. John's Wort (Hypericum perforatum)
Traditional Use
Hypericum perforatum has been used for centuries in European folk and ecclesiastical medicine, primarily for mood disorders, nerve pain, and digestive disturbances. Its use for intestinal complaints appears in 16th–18th century European herbals, where it was applied to inflammatory gut conditions and diarrhea.
Scientific Evidence
The review of herbal medicines for IBS that included Hypericum perforatum in its analysis found limited data. St. John's Wort exhibits mixed or inconsistent results in IBS, reflecting heterogeneity in study designs and underlying mechanisms. Its presumed relevance to IBS relates to its serotonergic mechanisms (inhibiting serotonin reuptake), which intersect with gut-brain axis dysfunction. However, robust human RCT data specifically for IBS are lacking.
Evidence strength: Insufficient for IBS specifically. The biological rationale (serotonergic activity) is plausible but not yet supported by adequate clinical evidence in this indication.
4.10 General Summary of Natural Ingredient Evidence
Clinical studies demonstrate that certain natural interventions, particularly peppermint oil, STW 5 (Iberogast), psyllium, and several selected probiotics, can provide modest but clinically meaningful symptom improvement, especially for abdominal pain. Nonetheless, heterogeneity in trial design, short durations, small sample sizes, and limited subtype stratification restrict the strength of the resulting recommendations.
5. Dietary Factors
5.1 The Low-FODMAP Diet
FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols) are short-chain fermentable carbohydrates that are poorly absorbed in the small intestine and rapidly fermented by colonic bacteria, producing gas, osmotic effects, and symptom exacerbation in sensitive individuals.
Low-FODMAP diets consistently alleviate IBS symptoms and improve quality of life. Low FODMAP diet and probiotics were shown to be effective for IBS in several systematic reviews. In the 2020 ACG guidelines, probiotics and a low FODMAP diet are recommended to alleviate IBS symptoms before escalating to medical therapies or as adjuncts to medical therapies.
However, the FODMAP-restricted diet may be effective in short-term management of selected patients with IBS, but more rigorous trials are needed to establish long-term efficacy and safety, particularly on colonic health and microbiome. Reviews often focus on short-term outcomes, leaving uncertainties about the long-term impact of dietary interventions on gut microbiota composition and inflammatory markers.
5.2 Dietary Fiber: Soluble vs. Insoluble
Not all dietary fiber has equivalent effects in IBS. Soluble fiber (e.g., psyllium, oat bran, ispaghula husk) tends to be better tolerated and more beneficial than insoluble fiber (e.g., wheat bran), which in some individuals can worsen bloating and pain. Research points to the necessity of personalizing dietary approaches based on individual responses and microbiota profiles to optimize treatment efficacy.
5.3 Gluten and Wheat Sensitivity
There is little evidence supporting the use of a gluten-free diet in IBS, and it is still ambiguous whether patients should increase their dietary fiber intake to mitigate IBS symptoms. Some individuals with IBS who respond to a gluten-free diet may in fact be responding to the parallel reduction of fructans (a FODMAP component of wheat) rather than to gluten itself. Celiac disease must be excluded before attributing symptoms to non-celiac gluten sensitivity.
5.4 Fat and Meal Size
High-fat meals are recognized dietary triggers in IBS, particularly for postprandial symptoms, through their stimulation of the gastrocolic reflex and effects on intestinal motility. The evidence base for fat restriction as a formal intervention is less well characterized by RCTs compared to the low-FODMAP approach, but it is discussed in authoritative clinical literature.
6. Lifestyle Factors
6.1 Psychological Stress and Mental Health
IBS is a highly prevalent functional gastrointestinal disease commonly associated with psychological comorbidities and maladaptive thought patterns. Previous studies report that psychological therapies such as cognitive behavioral therapy (CBT) and gut-directed therapy (GDT) improve IBS symptom management and quality of life. Psychiatric symptoms and disorders are an independent risk factor for the development of IBS and can exacerbate or perpetuate symptoms. Anxiety disorders can precipitate or worsen symptoms through associated heightened autonomic arousal (in response to stress) or through changes in gastrointestinal sensitivity and motor function.
6.2 Sleep Quality
Sleeping onset difficulties ≥ 3 times weekly were associated with IBS (OR: 2.153; 95% CI 1.228–3.774) after full adjustment for sociodemographic and lifestyle factors in a population-based Swedish study. IBS was associated with increased odds of both insomnia and hypersomnolence-related symptoms (ORs 1.9–4.0).
6.3 Physical Activity
Previous studies have linked IBS to individual factors such as stress, poor sleep, lack of dietary discipline, and physical activity. A Cochrane systematic review on physical activity for IBS (CD011497, 2022) has been published, indicating growing interest in this area. A cross-sectional association between sedentary behavior and IBS was reported, suggesting that a sedentary lifestyle may be an independent risk factor for IBS.
6.4 Comprehensive Lifestyle Approaches
A structured lifestyle medicine intervention for IBS has been explored. One such intervention included a 12-week period of structured sleep routine, compliance with a nocturnal sleep schedule, limiting screen time and caffeine consumption, stress management counseling and mindfulness-meditation, and physical activity tracking for at least 45 minutes per day. Studies demonstrate significant improvements in gastrointestinal symptoms and microbiota composition, highlighting the potential of dietary strategies to beneficially modify gut health.
References
- Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. New England Journal of Medicine. 2017. PubMed 30521231.
- Enck P, et al. Irritable bowel syndrome. Nature Reviews Disease Primers. 2016. PubMed 27159638.
- Iriondo-DeHond A, et al. The Role of Gut-Microbiota in the Pathophysiology and Therapy of Irritable Bowel Syndrome: A Systematic Review. PMC9477602.
- Pathophysiological Mechanisms and Nonpharmacological Interventions in Irritable Bowel Syndrome: Current Insights and Future Directions. PMC12800576.
- Unraveling the Pathophysiology of Irritable Bowel Syndrome: Mechanisms and Insights. PMC12607773.
- Mayer EA, et al. The Neurobiology of Irritable Bowel Syndrome. PMC10208985.
- Sperber AD, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021.
- Prevalence and Burden of Illness of Rome IV Irritable Bowel Syndrome in the United States. Gastroenterology. 2023.
- Vasant DH, et al. Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review. PMC10095554.
- Ghoshal UC, et al. The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy. Frontiers in Microbiology. 2019.
- Meta-analysis of gut microbiota alterations in patients with irritable bowel syndrome. Frontiers in Microbiology. 2024.
- Rhee SH, et al. The pathophysiology of irritable bowel syndrome: inflammation and motor disorder. PubMed 16498275.
- Simrén M. Pathophysiology of the irritable bowel syndrome – Reflections of today. PubMed 31594651.
- Mathur R, et al. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome – An Update. PMC7366247.
- Ghoshal UC, et al. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy. PMC5347643.
- Alammar N, et al. The impact of peppermint oil on the irritable bowel syndrome: a meta-analysis of the pooled clinical data. PMC6337770.
- Lacy BE, et al. Systematic review and meta-analysis: efficacy of peppermint oil in irritable bowel syndrome. Alimentary Pharmacology & Therapeutics. 2022.
- Khanna R, et al. Peppermint oil for the treatment of irritable bowel syndrome: a systematic review and meta-analysis. PubMed 24100754.
- Turmeric for Treatment of Irritable Bowel Syndrome: A Systematic Review of Population-Based Evidence. PMC9659538.
- Ng QX, et al. A Meta-Analysis of the Clinical Use of Curcumin for Irritable Bowel Syndrome (IBS). PMC6210149.
- A Systematic Review of the Efficacy and Safety of Turmeric in the Treatment of Digestive Disorders. PMC11168884.
- Khanna R, et al. Herbal Medicines for the Management of Irritable Bowel Syndrome: A Systematic Review. PMC5053451.
- Camilleri M, et al. Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. PMC5429330.
- Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis. PMC8959572.
- Dietary Interventions in Irritable Bowel Syndrome: A Systematic Review of Clinical Outcomes, Microbiota Changes, and Inflammatory Markers. PMC11524984.
- Moayyedi P, et al. Systematic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. PubMed 25903636.
- Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Clinical Trials. PubMed 39110917.
- Natural Products for the Treatment of Irritable Bowel Syndrome. Gastroenterology & Hepatology. September 2025.
- Natural Products for the Treatment of Irritable Bowel Syndrome. PMC12853684.
- Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines. Nutrients. 2026.
- Zejnelagic J, Ohlsson B. Chronic stress and poor sleeping habits are associated with self-reported IBS and poor psychological well-being in the general population. PMC8296624.
- Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management. PMC10237074.
- Psychological, physical, and sleep comorbidities and functional impairment in irritable bowel syndrome: Results from a national survey of U.S. adults. PMC7808669.
- Stress reduction and psychological therapy for IBS: a scoping review. Frontiers in Gastroenterology. 2024.
- Remission of irritable bowel syndrome with lifestyle medicine. PMC12302111.
- Targeting Irritable Bowel Syndrome Through Diet and Mechanism-Based Therapies: A Pathophysiological Approach. Nutrients. 2025.
Go back